Clinical Trial Update: Safety and Immunogenicity of Two Doses, Administered Three Weeks Apart, of Two Monovalent H5N1 Influenza Vaccines Containing 2 Doses of H5N1 Influenza Antigen, in Non-elderly Adult and Elderly Subjects [Phase 2]

View source ↗

Summary

Phase 2 study assessing safety and immunogenicity of two monovalent H5N1 influenza vaccines administered in two doses three weeks apart to non-elderly adults an…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pandemic H5n1 Influenza

Drugs mentioned

• H5N1 influenza vaccine (monovalent) - formulation 1 (H5N1 influenza vaccine, monovalent)
• H5N1 influenza vaccine (monovalent) - formulation 2 (H5N1 influenza vaccine, monovalent)

Snippet

Sponsor: Novartis Vaccines | Conditions: Pandemic H5N1 Influenza | Phase 2 | Status: COMPLETED